Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire November 2, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire November 1, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire October 31, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire October 30, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire October 29, 2023

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Fibrogen, Inc. (FGEN) Investigation

Accesswire October 27, 2023

FibroGen to Report Third Quarter 2023 Financial Results

GlobeNewswire October 23, 2023

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm

Accesswire October 6, 2023

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire September 27, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses to Contact the Firm

Accesswire September 25, 2023

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

GlobeNewswire August 29, 2023

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

Accesswire August 29, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

Accesswire August 25, 2023

FibroGen Reports Second Quarter 2023 Financial Results

GlobeNewswire August 7, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

Accesswire August 4, 2023

FibroGen Announces Leadership Transition

GlobeNewswire July 25, 2023

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

Accesswire July 25, 2023

FibroGen to Report Second Quarter 2023 Financial Results

GlobeNewswire July 24, 2023

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN

Newsfile July 23, 2023

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses In Excess of $100,000 to Contact the Firm

Accesswire July 21, 2023